English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Purpose: To investigate the frequency of gene CYP2C9 *3 in Chinese populations, and to analyze the impact of CYP2C9 *3 genetic polymorphism on the cholesterol-lowering effect of fluvastatin in a Chinese hyperlipidemic population. Methods: CYP2C 9 genotype was determined by polymerase chain reaction - restriction fragment length polymorphism (PCR - RFLP) in 270 unrelated hyperlipidemic patients who were treated with 80mg fluvastatin monotherapy daily for 4 weeks and 250 healthy controls. Clinical data were collected prior to treatment with fluvastatin and 4 weeks after. Results: In 270 hyperlipidemic patients, the frequency of CYP2C9 *3 was 3.70 % which is significantly higher than in 250 healthy controls (2.60 %) ( p < 0.01). After oral intake of fluvastatin 80 mg daily for 4 weeks, CYP2C9 *1/*3 genotype was associated with a decrease in LDL-C levels (by 33.9 % in CYP2C9 *1/*3 versus 24.5 % for CYP2C9 *1/*1, p < 0.05) and with reduction of TC (by 36.4 % in CYP2C9 *1/*3 versus 19.4 % in CYP2C9 *1/*1, p < 0.05). Conclusion: The frequency of CYP2C9 *3 is 3.17 % in Chinese populations, and those who carry CYP2C9 *3 mutation have a high risk of hyperlipidemia. CYP2C9 *3 seems to increase the lipid-lowering effects of fluvastatin. Keywords: Hyperlipidemia, Gene, CYP2C9 , Polymorphism, Polymerase chain reaction, Restriction fragment length polymorphism, Fluvastatin

Effect of <i>CYP2C9</i>*3 gene polymorphism on lipid-lowering efficacy of fluvastatin in a Chinese hyperlipidemic population